Comparing LAI and Oral Antipsychotic Options: Expert Discussions with Schizophrenia Case Reports
Comparing LAI and Oral Antipsychotic Options: Expert Discussions with Schizophrenia Case Reports is organized by CME Institute of Physicians Postgraduate Press, Inc. (PPP).
Activity opens: 04/06/2023
Activity expires: 4/30/2024
Program Description
On average, long-acting injectable antipsychotics (LAIAs) are often initiated late in adults with schizophrenia, despite evidence supporting early use. Leslie Citrome, MD, MPH, John Lauriello, MD, and Amber Hoberg PMHNP-BC discuss the latest guideline recommendations, benefits to early intervention services (EIS), barriers to initiating treatment with LAIAs, and compare efficacy and safety of LAIAs and oral medications in schizophrenia treatment. These data and considerations are then applied to real-world patient case studies as Drs Citrome and Lauriello and Amber determine the appropriate therapy for each patient, including their candidacy for treatment with LAIAs and how to switch from oral to LAI medication.
Learning Objectives:
After completing this educational activity, you should be able to:
• Examine data comparing the efficacy of LAIAs and oral medications.
• Analyze the clinical trial data and unique considerations of available LAIAs.
• Implement early integration of LAIA therapies in appropriate patients.